AMR, Sepsis and AKI: Global Risk and Biomarker Mitigation

Decorative image of the AMR Learning Lounge

AMR, Sepsis and AKI: Global Risk and Biomarker Mitigation

SUMMARY

Quickly assessing the risk of acute kidney injury (AKI) and treating incidents is essential to minimizing kidney damage and potentially restoring kidney function. With the assistance of biomarkers and syndromic testing, healthcare providers are equipped to appropriately mitigate the risks of AKI, antimicrobial resistance (AMR), and sepsis while managing patient care.

FEATURED EXPERTS

Chris Groke, PharmD, BCPS, BCIDP, Medical Science Liaison at bioMérieux

GET STARTED

Read the Learning Lounge exclusive article here.

Take Me There Now

Filename: LL-Editorial_AMR--Sepsis-and-AKI---Risk--amp--Mitigation---Chris-Groke_April2022.pdf
Size: 375 KB
Format: application/pdf

Read Time: 3 minutes

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

Global Solutions

VIDAS^® NEPHROCHECK^®

VIDAS^® NEPHROCHECK^® measures urinary TIMP-2 & IGFBP-7, specific urinary biomarkers for early risk assessment of moderate to severe Acute Kidney Injury (AKI). The VIDAS^® NEPHROCHECK^® assay is intended to be used in conjunction with clinical evaluation as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) in acutely ill patients.

Learn More

Us Solutions

NEPHROCHECK^®

The NEPHROCHECK Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment. The NEPHROCHECK Test System is intended to be used in patients 21 years of age or older.

Learn More

PUBLISHED BY

Learning Lounge Exclusive
May 2, 2022